Three proteins in mature myelin (Nogo, MAG, and OMgp) have been purported to be critical in causing both regenerative failure and minimal sprouting after CNS injury. However, the role of this repulsive trio in vivo has been controversial. Lee et al., in this issue of Neuron, provide evidence that genetically deleting all three major myelin inhibitors either singly or all together does not result in regeneration after spinal cord lesion, and the minimal sprouting that occurs, when it does, is insufficient to restore meaningful behavior.
In the English translation of S. Ramon y Cajal's legendary textbook ''Degeneration and Regeneration of the Nervous System'' (Ramon y Cajal, 1928) , he states that, ''It is doubtful whether there exists a negative neurotropism.'' On the contrary, he suggests that, in various instances of regeneration where there occur ''repulsive'' behaviors of axons, these types of retrogressive changes in axon trajectory can ''be explained simply by assuming the absence in such regions of positive neurotropic substances.'' While Ramon y Cajal appeared to deny the existence of actively inhibitory mechanisms that could curtail the forward progress of nerve growth, he was sufficiently forward thinking to suggest that ''.this point requires further investigation.'' It was not until the 1980s when Martin Berry first hypothesized that growthinhibitory molecules released from degenerating CNS myelin appeared to be adequate to explain many of the examples of both regenerative failure and regeneration success. Indeed, he pointed out the intriguing observations that in the few instances where regeneration does occur, at least in part (i.e., severed optic axons within the retina, cut olfactory nerves within the bulb, lesioned hypothalamo-hypophyseal tract axons, and certain injured axon pathways in the early fetal CNS), the regenerating fibers are nonmyelinated, or perhaps yet to be myelinated. The second half of the 1980s saw the first glimpses into the identification of specific, putatively inhibitory, molecules within CNS myelin. The Martin Schwab lab published several seminal papers reporting the repulsive growth characteristics of sensory neurons when they encounter CNS versus PNS tissue in vitro (see Caroni and Schwab, 1988) . This was followed by the demonstration of the inhibitory 35 and 250 kD protein fractions of adult myelin, and then by the discovery of the Inhibitor of Neurites-1 and -2 (IN-1/2) antibodies that neutralized the nonpermissive substrate properties of CNS white matter (Caroni and Schwab, 1988) . This paper in particular, appearing in the very first issue of Neuron, ignited an era of hope that merely cancelling out the inhibitory effects of myelin might lead to significant axon regeneration and robust functional recovery after spinal cord injury (Caroni and Schwab, 1988) . Over the following decades, the 250 kD protein-the major antigenic target of the IN-1 antibody-was finally identified as a member (Nogo-A, or Rtn4-A) of the so-called Reticulon proteins, with at least a part of the protein exposed at the oligodendrocyte surface (Oertle and Schwab, 2003) . This was accompanied by the discovery of at least two more major myelin-associated proteins with axonal growth inhibitory properties, MAG and OMgp, as well as the elucidation of the various receptors for this cadre of molecules in myelin that repelled regrowing axons (reviewed in Yiu and He, 2006) . Together, Nogo, MAG, and OMgp have come to be characterized as ''potent inhibitors'' and likely to act synergistically or at least redundantly to block axon regeneration. Indeed, many in vivo studies after spinal cord injury, especially those related to Nogo and its receptors using IN-1 and other (more specific) Nogo antibodies, Nogo receptor blocking peptides, receptor ectodomains, or various knockout mice, have purported to show modest to robust regeneration of major axon tracts through and sometimes well beyond the lesion (Li et al., 2004; Freund et al., 2006) . The claims of significant functional recovery using these strategies in rodents to primates have moved ever forward and, with the help of Novartis, humanized IN-1 antibodies are now being administered into human paraplegics.
In this latest issue of Neuron, 22 years after discovery of IN-1, Jae Lee and others from the lab of Binhai Zheng present results that make one wonder whether the wheels of progress toward clinical trials may, nonetheless, have spun too rapidly. To assess the combined contribution of the three dominant axon growth inhibitors in myelin, they generated a complete Nogo/MAG/OMgp triple null mutant and investigated its axon regrowth characteristics in comparison with single deletion animals in vitro and after cord injury. This is a very special null mutant, indeed, because it remains fully viable and morphologically normal, at least at a gross level, even with all three isoforms of Nogo (A, B, and C, encoded by the same gene) as well as OMgp and MAG missing. Western blot analyses of total brain protein extracts confirmed the complete absence of the three proteins and further indicated that the expression of their common receptors was not altered in the triple mutants.
The results of their laborious and carefully executed experiments on regeneration were remarkably negative. Taken together, the in vitro assays indicated that, for P7 cerebellar granule neurons as well as fully adult DRGs, deleting all three inhibitors, Nogo, MAG, and OMgp, did not lead to significantly more neurite outgrowth on myelin than deleting Nogo alone. For their critical in vivo regeneration experiments, they were especially thorough in their use of dorsal hemisection as well as complete transection models to study both the corticospinal tract (CST) and raphe-spinal (5-HT, serotonergic) tract in the single and triple knockout mice. Meticulous CST labeling and immunohistological studies of 5-HT proximal to, within, and beyond the lesion led the authors to conclude that deleting any one inhibitor (Nogo, MAG, or OMgp) or, most importantly, all three inhibitors simultaneously does not promote any significant CST or serotonergic axon regeneration through or beyond the lesion. While there were quite subtle behavioral defects in the intact mutants, the authors were cautious to assay for potential behavioral improvements after lesion that had been at baseline levels prior to injury. Consistent with the lack of enhanced axon regeneration, behavioral analyses did not reveal any significant improvements over controls.
What about compensatory axon sprouting? In 1998, a paper by Z'Graggen et al. (1998) from the Schwab lab began to explore the possibility that the inhibitory 35/250 kD proteins in myelin were not only involved with regeneration failure but also in limiting sprouting from both severed and intact axons. Unilateral CST lesions within the pyramid were generated in adult rats that were administered IN-1 antibodies. This was followed by BDA tracing of cortico-fugal axons and behavioral analyses. The results showed minimal regeneration of only a few axons into, but not through, the lesion and, in addition, a rather striking effect on sprouting of rostrally intact cortical projection axons across the midline into the red nucleus and pons contralateral to the lesioned side. Enhanced recovery of various CST-dependent forelimb behaviors, and importantly, their persistence after more proximal relesion of the pyramid, suggested that the purported sprouting was, in fact, the anatomical substratum underlying the return of function. This was also the first time that limiting sprouting/plasticity, in addition to frank regeneration through the lesion, was being considered as a major role that myelin inhibitors were playing after CNS injury. The mechanistic relationship between the various myelin inhibitors and the phenomenon of axonal sprouting has been the subject of investigation ever since and is also a critical aspect of the Lee et al. (2010) manuscript. Thus, to ascertain whether deleting the three myelin inhibitors enhances compensatory sprouting, again, two major descending pathways-the raphe-spinal and CSTswere studied, but this time using lateral hemisection and pyramidotomy models of regeneration failure. Interestingly, MAG and OMgp single mutants, but not Nogo mutants, exhibited a small but significant elevated level of 5-HT immunoreactivity on the denervated side as compared with wild-type mice. Again, surprisingly, this effect was not further enhanced in the triple mutants. On the other hand, Nogo null mutants exhibited enhanced CST sprouting, again at levels lower than expected based on previous studies. OMgp mutants did not differ significantly from controls and, strangely, MAG mutants even displayed reduced CST sprouting. This suggested that MAG has some sort of neuroprotective role, at least for CST axons, although this selectivity does not make obvious sense. Nonetheless, in line with this observation, the degree of CST sprouting in the triple mutants was similar to that of control mice (i.e., somewhere between Nogo and MAG mutants), suggesting antagonistic effects of deleting Nogo and MAG together. Nogo/OMgp double mutants remain to be studied in the Zheng lab. Thus, the effect of the three main myelin inhibitors on the regulation of sprouting is surely complicated and, most importantly, the modest degree of enhancement in axon sprouting observed in the various mutants was again insufficient to elicit any meaningful functional benefits. Therefore, the authors conclude that the physiological significance, if any, of the enhanced sprouting after deleting Nogo, MAG, OMgp, or all three still remains to be established.
The question remains: if myelin is as potently inhibitory as the published literature suggests, how could this negative outcome in the triple null animals have occurred? Perhaps there were hints all along-not just from the controversial results using injected reagents to block myelin inhibitory mechanisms, as well as the conflicting results from mutant animals (which may all be a result of incomplete lesions or labeling artifacts; Steward et al., 2007)-but from other results as well. Pettigrew and Crutcher (1999) demonstrated that neurons could regrow axons robustly on adult white matter if the sections were cut tangentially along a plain precisely parallel to the trajectory of the tract. Also, Davies et al. (1999) demonstrated that adult sensory neurons could, in fact, regenerate axons at rapid rates within not only intact but also degenerating myelinated fiber tracts when the neurons were microtransplanted to produce minimal scarring around the implant site. However, the regenerating axons abruptly halted their regrowth and became dystrophic when approaching the vicinity of proteoglycanrich scar tissue, just as they do after any CNS lesion. Simply modifying the proteoglycan matrix has consistently led to some functional regeneration, sprouting, or both, but again, the results of proteoglycan modification alone, without the use of additional strategies, have not been fantastic (García-Alías et al., 2009 ). Many studies have pointed and continue to point to both the lack of intrinsic growth potential in adult neurons (Park et al., 2008) and various inhibitory cell types and factors, in addition to proteoglycans, within the vicinity of the glial scar as further determinants of regeneration failure (Busch et al., 2010) . There are quite encouraging results showing that lengthy regeneration with incomplete functional recovery can be obtained when PNS bridging (supplying guidance, conditioning via trophic/tropic support, and remyelination) is combined with chondroitinase (allowing some regenerating axons in the bridge to exit and penetrate completely through the forming scars at the graft/host interfaces) (Houle et al., 2006) . Obviously, there are potent barriers to CNS regeneration that remain, although it would appear from Lee et al. (2010) that myelin inhibitors may not be among them. But the story does not end here and neither does the controversy.
A paper has just appeared from the lab of Stephen Strittmatter (Cafferty et al., 2010) in which comparisons of regeneration efficacy following hemilesions of the thoracic spinal cord were made in mutant mice singly, doubly, or triply lacking these same three myelin inhibitory proteins. The authors report striking axonal sprouting as well as regeneration of both 5-HT and CST axons through and well caudal to their T6-7 dorsal hemisection lesions, especially in the triple knockout mice. In addition, they report dramatically improved behavioral recovery in the triple null mice. The divergent results between the two studies seem, at face value, difficult to reconcile. I can only offer the suggestion that the differences may be due to the extent of damage created in the various injury models that were used. While the Lee et al. study used pyramidotomy, double cut dorsal hemisection, and complete transection for their injury models, Cafferty et al. used a single dorsal hemisection model. This may result in the sparing of a small portion of the lateralmost fibers of the CST, as well as those of the serotonergic system residing in the dorsal cord. In turn, enhanced, functionally effective local sprouting of this remaining contingent of axons may occur at and beyond the lesion epicenter in the absence of myelin inhibitors. One would also like to know if the purportedly regenerating axons within the distal tract lack myelin, at least at early stages. If they do, then this would be strong evidence in favor of regeneration.
At the very heart of this and other controversies in the broader field of regeneration biology lie two very interesting phenomena that can occur when one attempts to damage axons even with sufficient force to cut them. First, axons are far more resilient than one might expect from such a thin cellular extension. Indeed, it has been shown that axon tracts can be stretch grown at rates of 8 mm/d and reach lengths of a remarkable 10 cm without disconnection, far exceeding what one might have thought possible (Pfister et al., 2004) . Also, initially uncut but stretched axons, which tend to reside at the outermost edges of certain types of lesion-making devices, in turn become compromised and are likely to be at increased risk of secondary axotomy and dieback due to not only intrinsic mechanisms but also to inflammatory extravasations throughout the lesion. Any number of even minimally therapeutic interventions can help tip the balance and save these fibers (Busch et al., 2010) . Thus, their persistence in the treated or genetically altered animal, but not in the controls, may cause them to appear as regenerating fibers because they seem to have grown in an abnormal, meandering course around the lesion. But this is in fact an erroneous perception, because they were never cut in the first place. These types of anatomical subtleties can make it challenging to interpret the results from different lesion models. How these issues factor into the interpretation of the two studies presented here will likely be resolved over time. For now, definitive resolution of what roles Nogo and the other myelin inhibitors play after CNS injury remains ''To be continued.''
